Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass. , may 1, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted an aggregate of 10,600 restricted stock units (rsus) to four newly-hired employees, with a grant date of april 30, 2023.

KPTI Ratings Summary

KPTI Quant Ranking